According to HealthAffairs.org, a quartet of recent studies and reports from a variety of authors are shedding new light on the collective cost burdens posed by rare diseases, disorders, and conditions that combined affect between 25 and 30 million people in the United States.
Another article in from Health Payer Intelligence, highlights that Rare disease healthcare spending totaled around $966 billion in 2019, which exceeds the amount spent for most of the top chronic diseases like cancer and diabetes. Life Sciences and Medical Device companies looking to positively impact the cost of care and patient outcomes should start by ensuring their Medical Science Liaisons (MSLs) and field teams are engaging the the Key Opinion Leaders (KOLs) involved in treating rare disease patients and helping influence patients in making important decisions about managing their condition and obtaining the best possible care.
H1 took a look at its global HCP knowledge-base to surface the key influencers in the rare disease category. Download the infographic to see what we found.